SAB Biotherapeutics (SABS) Accounts Payables (2020 - 2026)

SAB Biotherapeutics has reported Accounts Payables for 7 years, with the latest figure at $5.4 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 113.72% year-over-year to $5.4 million; the trailing twelve-month figure through Mar 2026 stood at $5.4 million (up 113.72% YoY), and the FY2025 full-year result was $3.1 million, down 42.52% from the prior year.
• Accounts Payables for Q1 2026 stood at $5.4 million, up from $3.1 million in the prior quarter.
• The five-year high for Accounts Payables was $10.2 million in Q3 2022, with the low at $1.1 million in Q3 2023.
• Historically, Accounts Payables has averaged $4.1 million across 5 years, with a median of $3.1 million in 2025.
• Annual changes were most pronounced in 2023 — Accounts Payables sank 89.42% — and 2024, when it surged 260.03%.
• SAB Biotherapeutics' Accounts Payables stood at $9.9 million in 2022, then tumbled by 32.52% to $6.7 million in 2023, then slipped by 18.22% to $5.5 million in 2024, then slumped by 42.52% to $3.1 million in 2025, then surged by 71.23% to $5.4 million in 2026.
• The last three Accounts Payables figures came in at $5.4 million (Q1 2026), $3.1 million (Q4 2025), and $3.0 million (Q3 2025), per Business Quant data.